ArticleScientific reports2025
METTL14-mediated miR-122-5p maturation stimulated tumor progression by targeting KAT2A in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Obesity impairs spermatogenesis via Leydig cell ferroptosis induced by liver-derived exosomal miR-122-5p.Communications biology · 2026Article
- The metabolic-epigenetic interface: lysine succinylation orchestrates bidirectional crosstalk in neurodegenerative disorders.Frontiers in neurology · 2025Review
- The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
m6A modifications are involved in regulating microRNA (miRNA) processing and maturation, and are associated with tumor development. Therefore, this study was aimed to explore the mechanism of miR-122-5p in regulating hepatocellular carcinoma (HCC) progression. mRNA expression and transfection efficiency were detected by RT-qPCR. Western blot was employed to measure protein level. Cell functions were evaluated through CCK-8 and transwell, respectively. Intracellular m6A levels were analyzed by MeRIP. Dual luciferase reporter gene, RIP and co-IP were applied to verify the binding relationship. Xenograft tumor model was carried out for in vivo validation of miR-122-5p function. We reported that miR-122-5p was clearly lessened in HCC. Functionally, miR-122-5p introduction inhibited the malignant progression of HCC. Mechanistically, METTL14 insertion promoted miR-122-5p maturation by labeling pri-miR-122 with m6A. In addition, miR-122-5p exerted suppressor effects by targeting Lysine acetyltransferase 2 A(KAT2A). Moreover, we also found that KAT2A overexpression limited β-catenin expression through succinylation modification. Finally, animal data also illustrated that miR-122-5p introduction could hinder the growth of HCC tumors in vivo. We revealed the existence of a METTL14/miR-122-5p/KAT2A/β-catenin mechanistic axis in HCC, which has not been reported in the literature. This newly discovered mechanistic axis may provide new ideas for HCC therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.